On April 30, 2025, Evaxion Biotech A/S held its Annual General Meeting where 75.2% of shares voted; key decisions included approving a loss transfer to the next year, re-electing board members, and authorizing the issuance of warrants and share capital increase of up to DKK 100 million without pre-emptive rights.